CLOPIDOGREL 75 MG
CLOPIDOGREL (CLOPIDOGREL BISULFATE) : 75 MG · DIN 02385813 · SIVEM PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is CLOPIDOGREL?
CLOPIDOGREL 75 MG contains CLOPIDOGREL (CLOPIDOGREL BISULFATE) : 75 MG. It is listed in the Health Canada Drug Product Database under DIN 02385813, held by SIVEM PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Jun-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CLOPIDOGREL used for?
Secondary prevention of atherothrombotic events in patients with atherosclerosis (MI, stroke, PAD); Acute Coronary Syndrome (with ASA); Atrial Fibrillation (with ASA) in specific patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02385813 |
|---|---|
| Brand name | CLOPIDOGREL |
| Generic / active ingredient | CLOPIDOGREL (CLOPIDOGREL BISULFATE) : 75 MG |
| Manufacturer | SIVEM PHARMACEUTICALS ULC |
| Strength | 75 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AC04 CLOPIDOGREL |
| AHFS class | 20:12.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Jun-2012 |
| Original market date | 2012-06-11 00:00:00 |
How is it administered?
75 mg once daily. For ACS: 300 mg loading dose then 75 mg daily with ASA. Administer orally with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (Section 11 mentioned in TOC but content not in snippet). Typical USP standards apply.
How is it supplied?
Blisters of 30 tablets; bottles of 100 and 500 tablets.
Contraindications
Hypersensitivity to the drug/ingredients; active bleeding (peptic ulcer, ICH); significant liver impairment or cholestatic jaundice; concomitant use of repaglinide.
Warnings and precautions
Risk of increased bleeding; CYP2C19 poor metabolizers have diminished response; Thrombotic Thrombocytopenic Purpura (TTP) reported; cross-reactivity among thienopyridines.
Is CLOPIDOGREL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B01AC04 CLOPIDOGREL. 19 of 39 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-CLOPIDOGREL | 75 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02431971 |
| APO-CLOPIDOGREL | 300 MG | TABLET | APOTEX INC | MARKETED | DIN 02398591 |
| APO-CLOPIDOGREL | 75 MG | TABLET | APOTEX INC | MARKETED | DIN 02252767 |
| AURO-CLOPIDOGREL | 75 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02416387 |
| BIO-CLOPIDOGREL | 75 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02444895 |
| CLOPIDOGREL | 75 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02400553 |
| CLOPIDOGREL | 75 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02394820 |
| JAMP-CLOPIDOGREL | 75 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02415550 |
| M-CLOPIDOGREL | 75 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02502283 |
| MAR-CLOPIDOGREL | 75 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02422255 |
Who else supplies CLOPIDOGREL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CLOPIDOGREL appears in 321 registered pack listings across 14 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.